Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The €500 million deal is Tessellate's first with a pharmaceutical company and focuses on advancing synthetic lethality therapies ...

Joenja will be the first drug specifically for APDS to be reimbursed within the NHS and is available immediately in England and soon will be in Wales.

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.